MedinGlobal

Edit Template

CRESP 100

In Stock

CRESP 100 contains Darbepoetin alfa 100mcg and is listed as a prescription product marketed by Dr Reddy’s Laboratories Ltd. It belongs to the erythropoiesis-stimulating agent class and may be prescribed for selected anemia associated with chronic kidney disease or chemotherapy. Its active ingredient stimulates bone marrow production of red blood cells. Treatment requires specialist supervision, with hypertension and thrombotic risks requiring appropriate monitoring.

Medinglobal provides medicine information and enquiry coordination. It does not manufacture, sell or dispense medicines directly. Availability and any subsequent supply are subject to verification by an appropriately authorised independent provider and applicable regulations.

CRESP 100 – Composition, Uses and Medicine Enquiries

Product Overview

CRESP 100 is listed as a prescription product containing Darbepoetin alfa 100mcg, marketed in the source catalogue by Dr Reddy’s Laboratories Ltd.

It belongs to the erythropoiesis-stimulating agent class and may be prescribed for selected anemia associated with chronic kidney disease or chemotherapy.

Its active ingredient stimulates bone marrow production of red blood cells.

Treatment suitability depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.

Hypertension and thrombotic risks require specialist monitoring.

Composition and Strength

The supplied product information identifies the following composition:

Active Ingredient Strength
Darbepoetin alfa 100mcg

Product Name: CRESP 100

Generic Name: Darbepoetin alfa

Brand Name: CRESP 100

Strength: 100mcg

Listed Marketer: Dr Reddy’s Laboratories Ltd

The composition and strength should be verified against the original manufacturer-labelled packaging before publication or any medicine enquiry.

Therapeutic Category and Indication

CRESP 100 belongs to the erythropoiesis-stimulating agent category.

It may be prescribed for selected anemia associated with chronic kidney disease or chemotherapy.

Darbepoetin alfa stimulates bone marrow production of red blood cells.

Treatment choice depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.

Hypertension and thrombotic risks require specialist monitoring.

Administration Information

The supplied product information identifies injection by a healthcare professional according to monitored haemoglobin targets.

Administration should follow the treating clinician’s instructions and the approved product label.

Patients should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.

The exact dosage form and administration schedule must be verified against the approved product information.

Product Presentation and Availability

The product enquiry can be made using the following details:

  • Product Name: CRESP 100
  • Generic Name: Darbepoetin alfa
  • Strength: 100mcg
  • Company Name: Dr Reddy’s Laboratories Ltd
  • Therapeutic Category: Erythropoiesis-Stimulating Agent
  • Medicine Class: Erythropoiesis-Stimulating Agent (ESA)
  • Indication: Selected anemia associated with chronic kidney disease or chemotherapy
  • Administration: Injection by healthcare professional according to monitored haemoglobin targets

The exact dosage form, pack size, batch, storage, expiry and product-specific presentation require verification from original manufacturer packaging and an authorised provider.

Product details and supply eligibility may vary by country. A product listing does not confirm current stock or availability.

Prescription and Patient Safety

CRESP 100 is listed as a prescription product and requires specialist supervision.

Treatment suitability, contraindications, interactions and monitoring requirements must be evaluated by the treating specialist.

Hypertension and thrombotic risks require specialist monitoring.

Patients should follow the approved product label and their healthcare professional’s instructions. The dose and treatment schedule should not be changed without medical advice.

Medicine Enquiry Coordination Through Medinglobal

Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.

Medinglobal does not itself sell, dispense, manufacture or export medicines.

Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.

How to Submit a CRESP 100 Enquiry

To help identify the requested product, include the following details:

  1. Product name: CRESP 100.
  2. Generic name: Darbepoetin alfa.
  3. Required strength: 100mcg.
  4. Required formulation and quantity.
  5. Destination country.
  6. Valid prescription or institutional documents, where required.

Medinglobal may coordinate an introduction to a suitably authorised provider. The provider independently verifies product details, regulatory eligibility and any transaction.

Frequently Asked Questions

What is CRESP 100 used for?

CRESP 100 is associated with selected anemia related to chronic kidney disease or chemotherapy. The treating prescriber confirms the approved use.

What is the composition of CRESP 100?

The supplied catalogue lists Darbepoetin alfa 100mcg as its active ingredient. The composition should be verified against the original product packaging.

How is CRESP 100 administered?

The supplied information identifies injection by a healthcare professional according to monitored haemoglobin targets.

Which company is listed for CRESP 100?

Dr Reddy’s Laboratories Ltd is listed as the marketer in the supplied product information.

Does CRESP 100 require medical supervision?

Yes. Hypertension and thrombotic risks require specialist monitoring.

Can Medinglobal supply CRESP 100 directly?

No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.

Product Name

Generic Name

Brand Name

Composition

Strength

Therapeutic Category

Medicine Class

Indication

Dosage Form

Route of Administration

Reviews

There are no reviews yet.

Be the first to review “CRESP 100”

Your email address will not be published. Required fields are marked *

Pharmaceutical Disclaimer

Medinglobal Platform does not sell, dispense, manufacture or prescribe medicines. Pharmaceutical information on this page is provided solely for general information, product identification and enquiry coordination. Product listing is not medical advice, a recommendation or an offer for sale by Teji Radiance or the Medinglobal Partnership Firm. Prescription medicines require a valid prescription where applicable. Any regulated pharmaceutical activity is undertaken by the relevant independent provider subject to applicable law. Always consult an appropriately qualified healthcare professional before using or changing any medicine.

Scroll to Top